LAVIPHARM S.A. NA EO 1
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and… Read more
LAVIPHARM S.A. NA EO 1 (BXA0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, LAVIPHARM S.A. NA EO 1 (BXA0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
LAVIPHARM S.A. NA EO 1 - Net Assets Trend (None–None)
This chart illustrates how LAVIPHARM S.A. NA EO 1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LAVIPHARM S.A. NA EO 1 (None–None)
The table below shows the annual net assets of LAVIPHARM S.A. NA EO 1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to LAVIPHARM S.A. NA EO 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
LAVIPHARM S.A. NA EO 1 Competitors by Market Cap
The table below lists competitors of LAVIPHARM S.A. NA EO 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Hi-Road Food Technology Co. Ltd.
SHE:300915
|
$72.43 Million |
|
DT Cloud Star Acquisition Corporation Units
NASDAQ:DTSQU
|
$72.44 Million |
|
MSP Steel & Power Limited
NSE:MSPL
|
$72.46 Million |
|
Elanders AB Series B
LSE:0JBY
|
$72.49 Million |
|
Relais Group Oyj
HE:RELAIS
|
$72.40 Million |
|
Hong-Wei Electrical Industry & Co., Ltd.
TWO:4565
|
$72.40 Million |
|
Next Vision Stabilized Systems
TA:NXSN
|
$72.39 Million |
|
Centrum Medyczne ENEL-MED SA
WAR:ENE
|
$72.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LAVIPHARM S.A. NA EO 1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares LAVIPHARM S.A. NA EO 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently LAVIPHARM S.A. NA EO 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares LAVIPHARM S.A. NA EO 1's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LAVIPHARM S.A. NA EO 1 (BXA0) | €- | N/A | N/A | $72.41 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |